Natural killer (NK) cells are under extensive research for the treatment of various types of malignancies such as cancer and infectious disease. Various studies have been conducted which come out with positive results in order to check the safety and efficacy of NK cell therapies against the prevailing disease.
Access Full Report @ https://www.databridgemarketresearch.com/es/reports/global-natural-killer-nk-cell-therapeutics-market
These results demonstrated that NK cell therapies are the next promising immunotherapeutic approach for the treatment of cancer and infectious disease.
Data Bridge Market Research analyzes that the Global Natural Killer (NK) Cell Therapeutics Market is expected to grow with a CAGR of 43.1% in the forecast period of 2023 to 2030 and is expected to reach USD 4,805.25 million by 2030. The NK cell therapies segment is projected to propel the market growth due to the increasing patient population with chronic diseases worldwide.
Key Findings of the Study
Advancements in Natural Killer (NK) Cell Therapies
Several advancements in NK cell therapies are taking place, which is likely to accelerate the usage of NK cell therapies over other immune therapies used for the treatment of cancer, infectious diseases, and other malignancies. These advancements led to the development of safe and effective NK cell therapeutic approaches for the treatment of several kinds of malignancies.
Continuous advancements are taking place in order to provide patients with innovative approaches to achieve treatment against various types of malignancies. These advancements pave the way for physicians to offer patients the best therapeutic approach. This, thus, signifies that advancement in NK cell therapies acts as an opportunity for market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in Million and Pricing in USD
|
|
Segments Covered
|
Therapeutics (NK Cell Therapies and NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, and Others), End User (Research & Academic Institutes, Hospitals, and Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and rest of Middle East and Africa
|
|
Market Players Covered
|
Merck KGaA (Germany), Bristol-Myers Squibb Company (U.S.), Glycostem (Netherlands), Sanofi (France), Cytovia Therapeutics (U.S.), ImmunityBio, Inc. (U.S.), Biohaven Pharmaceuticals (U.S.), Fate Therapeutics (U.S.), EMERcell (France), Phio Pharmaceuticals (U.S.), PersonGen BioTherapeutics (China), Innate Pharma, Inc. (U.S.), INmuneBIO (U.S.), Gamida Cell (U.S.), Acepodia Inc. (U.S.), Affimed GmbH (Germany), Multimmune GmbH (Germany), iCell Gene Therapeutics (U.S.), Takeda Pharmaceutical Company Limited (Japan), Regeneron Pharmaceuticals Inc. (U.S.), and Bellicum Pharmaceuticals, Inc. (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, and regulatory framework.
|
Segment Analysis:
The global natural killer (NK) cell therapeutics market is categorized into five notable segments based on therapeutics, approaches, application, end-user, and distribution channel.
- Based on therapeutics, the market is segmented into NK cell therapies and NK cell directed antibodies. In 2023, the NK cell therapies segment is expected to dominate the market with a market share of 100.00% and is expected to reach USD 3,065.88 million by 2030, growing with a CAGR of 34.2% in the forecast period of 2023 to 2030.
In 2023, the NK cell therapies segment is expected to dominate the market as NK cells are innate cytotoxic lymphocytes involved in the surveillance and elimination of cancer. Moreover, several advances have been made in NK cell therapies such as target recognition, adoptive therapy, and improvement in cellular cytotoxicity.
- Based on approaches, the market is segmented into Antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies. In 2023, the antibody-dependent cell-mediated cytotoxicity (ADCC) segment is expected to dominate the market with a market share of 100.00% and is expected to reach USD 4,673.03 million by 2030, growing with a CAGR of 42.5% in the forecast period of 2023 to 2030.
- Based on application, the market is segmented into cancer, immunoproliferative disorders, acute infectious diseases, gastrointestinal diseases, and others. In 2023, the cancer segment is expected to dominate the market with a market share of 100.00% and is expected to reach USD 4,349.67 million by 2030, growing with a CAGR of 41.1% in the forecast period of 2023 to 2030.
- Based on end user, the market is segmented into hospitals, specialty clinics, and research & academic institutes. In 2023, the hospitals segment is expected to dominate the market with a market share of 84.73% and is expected to reach USD 4,020.78 million by 2030, growing with a CAGR of 42.8% in the forecast period of 2023 to 2030.
- Based on distribution channel, the market is segmented into hospital pharmacies, direct tender, and others. In 2023, the hospital pharmacies segment is expected to dominate the market with a market share of 92.20% and is expected to reach USD 4,456.19 million by 2030, growing with a CAGR of 43.2% in the forecast period of 2023 to 2030.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in the global Natural Killer (NK) cell therapeutics market that include Merck KGaA (Germany), Bristol-Myers Squibb Company (U.S.), Glycostem (Netherlands), Sanofi (France), Cytovia Therapeutics (U.S.), ImmunityBio, Inc. (U.S.), Biohaven Pharmaceuticals (U.S.), Fate Therapeutics (U.S.), EMERcell (France), Phio Pharmaceuticals (U.S.), PersonGen BioTherapeutics (China), Innate Pharma, Inc. (U.S.), INmuneBIO (U.S.), Gamida Cell (U.S.), Acepodia Inc. (U.S.), Affimed GmbH (Germany), Multimmune GmbH (Germany), iCell Gene Therapeutics (U.S.), Takeda Pharmaceutical Company Limited (Japan), Regeneron Pharmaceuticals Inc. (U.S.), and Bellicum Pharmaceuticals, Inc. (U.S.) among others.
Market Development
- In January 2022, Takeda acquired Adaptate Biotherapeutics to develop new gammadelta (γδ) T-cell activation therapies targeting solid tumors. With the acquisition, Takeda will acquire Adaptate's antibody-based γδ T-cell engagement platform, including preclinical candidates and discovery programs. Adaptate's γδ T-cell binders are designed to specifically modulate γδ T-cell-mediated immune responses at tumor sites while sparing damage to healthy cells. This acquisition will help the company focus on R&D.
- In January 2022, Gamida Cell provided an update on the omidubicel BLA submission. The company announced that following receipt of positive Type B meeting correspondence from the U.S. FDA, the company plans to initiate a rolling Biologics License Application (BLA) submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant. This has helped the company to expand its product portfolio.
- In February 2022, Affimed announced the publication of preclinical data demonstrating the cytotoxic potency and efficacy of NK cells pre-complexed with innate cell engagers after freezing & thawing. The data show experimental results of NK cells pre-complexed with three bispecific, tetravalent ICE molecules targeting the validated tumor target EpCAM and one of the NK cell-activating receptors CD16A, NKG2D, or NKp46. This has helped the company to proceed with further trials.
- In January 2021, Kiadis announced multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR. A clinical-stage biopharmaceutical company developed innovative NK-cell-based medicines for the treatment of life-threatening diseases. The company announced that four abstracts related to its K-NK-cell therapy platform were accepted for presentation at the TCT Meetings, the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blood & Marrow Transplant Research (CIBMTR).
- In December 2021, Nektar Therapeutics reported Phase 1b data for the new T-regulatory cell stimulator NKTR-358 (LY3471851) in patients with atopic dermatitis. NKTR-358 is designed to treat autoimmune and inflammatory conditions by correcting an imbalance in the immune system caused by an increase in the number of inflammatory T cells and a decrease in the number and function of immune regulatory Treg cells. This helped the company to focus on R&D in the later stages.
Regional Analysis
Geographically, the countries covered in the global natural killer (NK) cell therapeutics market report are the U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the dominant region in the global natural killer (NK) cell therapeutics market during the forecast period 2023-2030
In 2023, North America dominated the global natural killer (NK) cell therapeutics market owing to the higher level of investments by U.S. manufacturers and the increasing prevalence of chronic diseases in the U.S. North America will continue to dominate the market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology and the launch of new products in this region. Additionally, the increasing number of cases of chronic problems and advancement in NK cell therapies are expected to drive the market growth rate in this region.
Asia-Pacific is estimated to be the fastest-growing region in the global natural killer (NK) cell therapeutics market for the forecast period 2023-2030
Asia-Pacific is expected to grow during the forecast period due to the presence of major market players and the rapid development of medical facilities in emerging economies in this region. In addition to this, the rising level of healthcare expenditure and increasing per-capita income are expected to propel the market growth rate in this region.
For more detailed information about the global natural killer (NK) cell therapeutics market report, click here – https://www.databridgemarketresearch.com/es/reports/global-natural-killer-nk-cell-therapeutics-market
